Literature DB >> 32048861

PD-1 Deficiency Promotes Macrophage Activation and T-Helper Cell Type 1/T-Helper Cell Type 17 Response in Pneumocystis Pneumonia.

Chao Zhang1, Heng-Mo Rong1, Ting Li1, Kan Zhai1, Zhao-Hui Tong1.   

Abstract

Pneumocystis is an unusual, opportunistic fungal pathogen capable of causing Pneumocystis pneumonia (PCP) in immunocompromised hosts. Although PCP was discovered >100 years ago, its pathogenesis remains unclear. The inhibitory receptor PD-1 (programmed death 1), a negative regulator of activated T cells, has been reported to take part in tumor escape, immune tolerance, and infection immunity. In this study, we examined the role of the PD-1/PD-L1 (programmed death-ligand 1) pathway in patients with PCP and in mice. The expression levels of PD-1/PD-L1 in patients with PCP and in mice were measured by real-time PCR and flow cytometry. The effects of PD-1 deficiency are demonstrated using wild-type and PD-1-/- mice. Our data show that Pneumocystis infection promotes PD-1/PD-L1 expression; PD-1 deficiency enhances the phagocytic function of macrophages and the pulmonary T-helper cell type 1 (Th1)/Th17 response, which might contribute to Pneumocystis clearance; and PD-1 deficiency affects the polarization of macrophages. PCP mice treated with anti-PD-1 antibody showed improved pulmonary clearance of Pneumocystis. Collectively, our results demonstrate that the PD-1/PD-L1 pathway plays a role in regulating the innate and adaptive immune responses, suggesting that manipulation of this pathway may constitute an immunotherapeutic strategy for PCP.

Entities:  

Keywords:  PD-1; Pneumocystis; T cell; macrophage; pneumonia

Year:  2020        PMID: 32048861     DOI: 10.1165/rcmb.2019-0234OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  6 in total

1.  PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages.

Authors:  Yukiko Yamaguchi; Jackson Gibson; Kevin Ou; Lupita S Lopez; Rachel H Ng; Neena Leggett; Vanessa D Jonsson; Jelani C Zarif; Peter P Lee; Xiuli Wang; Catalina Martinez; Tanya B Dorff; Stephen J Forman; Saul J Priceman
Journal:  J Immunother Cancer       Date:  2022-06       Impact factor: 12.469

2.  Pneumocystis Pneumonia: Checkpoint Inhibition to the Rescue?

Authors:  Julian Better; Ulrich Matt
Journal:  Am J Respir Cell Mol Biol       Date:  2020-06       Impact factor: 6.914

3.  Correlation of SARS‑CoV‑2 to cancer: Carcinogenic or anticancer? (Review).

Authors:  Ying-Shuang Li; Hua-Cheng Ren; Jian-Hua Cao
Journal:  Int J Oncol       Date:  2022-03-02       Impact factor: 5.650

4.  Efficacy of phentolamine combined with ambroxol aerosol inhalation in the treatment of pediatric severe pneumonia and its effect on serum IL-10 and CRP levels.

Authors:  Junxia Li; Haixia Wu; Jingyao Zhang
Journal:  Transl Pediatr       Date:  2022-01

Review 5.  [Pneumocystis jirovecii Pneumonia in Patients with Lung Cancer: A Review].

Authors:  Ting Li; Jianying Zhou; Qing Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-03-28

6.  Diagnostic Value of Color Doppler Flow Imaging Combined with Serum CRP, PCT, and IL-6 Levels for Neonatal Pneumonia.

Authors:  Wenru Chen; Xiaoqing Yu
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-10       Impact factor: 2.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.